Recursion Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXRX research report →
Companywww.recursion.com
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
- CEO
- Najat Khan
- IPO
- 2021
- Employees
- 800
- HQ
- Salt Lake City, UT, US
Price Chart
Valuation
- Market Cap
- $1.32B
- P/E
- -2.80
- P/S
- 19.97
- P/B
- 1.53
- EV/EBITDA
- -1.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -34.44%
- Op Margin
- -882.92%
- Net Margin
- -844.46%
- ROE
- -54.32%
- ROIC
- -47.11%
Growth & Income
- Revenue
- $74.68M · 26.92%
- Net Income
- $-644,759,000 · -39.06%
- EPS
- $-1.44 · 14.79%
- Op Income
- $-648,132,000
- FCF YoY
- -1.45%
Performance & Tape
- 52W High
- $7.18
- 52W Low
- $2.77
- 50D MA
- $3.31
- 200D MA
- $4.35
- Beta
- 1.05
- Avg Volume
- 13.73M
Get TickerSpark's AI analysis on RXRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Hallett David | other | 26,657 |
| May 15, 26 | Khan Najat | other | 62,701 |
| May 15, 26 | Taylor Ben R | other | 25,018 |
| May 15, 26 | Gibson Christopher | other | 22,821 |
| May 7, 26 | Gibson Christopher | other | 60,000 |
| May 7, 26 | Gibson Christopher | other | 60,000 |
| May 7, 26 | Gibson Christopher | sell | 40,000 |
| May 7, 26 | Gibson Christopher | other | 20,000 |
| May 5, 26 | Borgeson Blake | sell | 30,000 |
| Apr 22, 26 | Gibson Christopher | other | 40,000 |
Our RXRX Coverage
We haven't published any research on RXRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RXRX Report →